PCI Biotech Holding ASA Company Description

PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform.

The company’s technology platform consists of a proprietary small molecule photosensitiser (fimaporfin) and a light source; and develops photochemical internalisation (PCI), inducing light-triggered intracellular release for various therapeutic modalities, as well as photochemical lysis (PCL) comprising light-triggered cell lysis, which enhances yield and purity in viral vector manufacturing.

It also explores for intratumoural immunotherapy therapeutics that identifies novel treatment combinations to overcome resistance to immune-checkpoint inhibitors and safety-issues associated with treatments; and develops nucleic acid therapeutics to improve the treatment of dermatological diseases.

In addition, the company develops fimaVACC for immunotherapy indications, which is in pre-clinical study; fimaNAc, a nucleic acid therapeutics delivery technology, which is in pre-clinical study for bioprocessing and dermatology indications; and technology for viral vector manufacturing and pre-clinical research for intratumoural immunotherapy.

PCI Biotech Holding ASA was incorporated in 2007 and is headquartered in Oslo, Norway.

PCI Biotech Holding ASA

Country	Norway
Founded	2007
Industry	Biotechnology
Sector	Healthcare
Employees	6
CEO	Ronny Skuggedal

Contact Details

Address: UllernchaussEen 64 Oslo, 0379 Norway
Phone	47 67 11 54 00
Website	pcibiotech.com

Stock Details

Ticker Symbol	PCIB
Exchange	Oslo Børs
Fiscal Year	January - December
Reporting Currency	NOK
ISIN Number	NO0010405640
SIC Code	2836

Key Executives

Name	Position
Ronny Skuggedal	Chief Executive Officer and Chief Financial Officer
Dr. Anders Hogset Ph.D.	Chief Scientific Officer